APA (7th ed.) Citation

CS, W., A, F., JM, W., M, H., J, R., L, L., . . . DJ, M. (2026). Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1. Diabetes care, 49(1), 111. https://doi.org/10.2337/dc25-1444

Chicago Style (17th ed.) Citation

CS, Wilson, et al. "Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1." Diabetes Care 49, no. 1 (2026): 111. https://doi.org/10.2337/dc25-1444.

MLA (9th ed.) Citation

CS, Wilson, et al. "Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1." Diabetes Care, vol. 49, no. 1, 2026, p. 111, https://doi.org/10.2337/dc25-1444.